SDC1 and neoplasm: Several studies have reported high stromal- or tumour-specific CD138 to be associated with poor patient outcome in various types of cancer, including EOC [35–37] and Rousseau et al. described CD138 as a promising new target for immunotherapy in metastatic breast cancer [38].